Akin Akinc
About Akin Akinc
Akin Akinc Chief Executive Officer
Akin Akinc is the Chief Executive Officer of Aera Therapeutics, having assumed the role in 2022. With a strong background in pharmaceutical research and development, Akin brings extensive expertise to the company, leading its strategic vision and operational execution. His experience in navigating complex drug development processes positions him well to guide Aera Therapeutics in its mission to advance therapeutic solutions.
Akin Akinc's Experience at Alnylam Pharmaceuticals
Akin Akinc spent nearly two decades at Alnylam Pharmaceuticals, where he held various roles in research and development as well as commercial sectors. Most recently, he served as the Senior Vice President and Head of Oncology. During his tenure, Akin was instrumental in leading several key programs, including the GIVLAARI® program, which he guided from Phase 3 clinical trials to its FDA approval and launch for treating acute hepatic porphyria in adults in 2019. Additionally, he led the fitusiran program from discovery to Phase 3 clinical stage, and co-led efforts aimed at the delivery of RNAi therapeutics.
Akin Akinc's Role in the Development of GIVLAARI®
One of Akin Akinc's notable contributions at Alnylam Pharmaceuticals was his leadership in the GIVLAARI® program, particularly from Phase 3 clinical trials to its subsequent approval and market launch. GIVLAARI® became the first treatment approved by the U.S. FDA for adults with acute hepatic porphyria in 2019. His pivotal role in this program underscores his capacity to steer complex pharmaceutical projects to successful outcomes.
Akin Akinc's Educational Background
Akin Akinc holds a Bachelor of Science in Engineering (BSE) in chemical engineering from Princeton University. He furthered his education with a Ph.D. in chemical engineering from the Massachusetts Institute of Technology (MIT). His educational foundation in chemical engineering has been instrumental in his career, enabling him to contribute significantly to the development of innovative pharmaceutical technologies and therapeutics.
Akin Akinc and Alnylam's RNAi Platform Technology
During his time at Alnylam Pharmaceuticals, Akin Akinc was involved in the development of the company's RNAi platform technology. Working on lipid nanoparticles, he played a key role in advancing this technology, which is fundamental for the delivery of RNAi therapeutics. His efforts in this area have been crucial in progressing RNAi therapeutic delivery methodologies, showcasing his expertise and commitment to innovative biomedical solutions.